Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research

Research output: Contribution to journalArticle

Authors

  • Victoria T Potter
  • Simona Iacobelli
  • Anja van Biezen
  • Johann Maertens
  • Jean-Henri Bourhis
  • Jakob R Passweg
  • Ibrahim Yakhoub-Agha
  • Reza Tabrizi
  • Jacques-Olivier Bay
  • Patrice Chevallier
  • Yves Chalandon
  • Anne Huynh
  • Jean Yves Cahn
  • Per Ljungman
  • Stig Lenhoff
  • N H Russell
  • Nathalie Fegueux
  • Gerard Socié
  • Bruno Benedetto
  • Ellen Meijer
  • G J Mufti
  • Theo de Witte
  • Marie Robin
  • Nicolaus Kröger

Colleges, School and Institutes

External organisations

  • Department of Haematological Medicine, Kings College Hospital, London, United Kingdom. Electronic address: victoriapotter@nhs.net.
  • Centro Interdipartimentale di Biostatistica e Bioinformatica, Università Tor Vergata, Roma, Italy.
  • European Society for Blood and Marrow Transplant Research Data Office, Leiden University Medical Centre, Leiden, Netherlands.
  • Division of Hematology, Uz Gasthuisberg, Leuven, Belgium.
  • Division of Hematology, Institut Gustave Roussy, Villejuif, France.
  • Division of Hematology, University Hospital of Basel, Basel, Switzerland.
  • Hôpital HURIEZ, Lille, France.
  • Division of Hematology, CHU, Bordeaux, France.
  • Service de Thérapie Cellulaire et d'hématologie clinique adulte, Hotel-Dieu, Clermont-Ferrand, France.
  • Division of Hematology, CHU, Nantes, France.
  • Division of Hematology, HUG, Geneva, Switzerland.
  • CHU Dept. Hematologie, Hopital de Purpan, Toulouse, France.
  • Hématologie Clinique, Hospital A. Michallon, Grenoble, France.
  • Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Hematology, Skanes University Hospital, Lund, Sweden.
  • Nottingham City Hospital, Nottingham, United Kingdom.
  • Départment d'Hématologie Clinique, Montpellier, France.
  • Department of Hematologie-BMT, Hospital St. Louis, Paris, France.
  • S.S.C.V.D. Trapianto di Cellule Staminali, A.O.U. Citta della Salute e della Scienza di Torino Presidio Molinette, Torino, Italy.
  • Department of Hematology, VU University Medical Center, Amsterdam, Netherlands.
  • King's College London
  • Department of Tumorimmunology Radboud University Medical Centre, Nijmegen, Netherlands.
  • Division of Hematology - Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France.
  • Department of Stem Cell Transplantation University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Abstract

The European Society for Blood and Marrow Transplant Research data set was used to retrospectively analyze the outcomes of hypomethylating therapy (HMA) compared with those of conventional chemotherapy (CC) before hematopoietic stem cell transplantation (HSCT) in 209 patients with advanced myelodysplastic syndromes. Median follow-up was 22.1 months and the median age of the group was 57.6 years with 37% of the population older than > 60 years. The majority of patients (59%) received reduced-intensity conditioning and 34% and 27% had intermediate-2 and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients did not achieve complete remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not significantly different between HMA and CC for overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM): OS (42% versus 35%), RFS (29% versus 31%), CIR (45% versus 40%), and NRM (26% versus 28%). Comparing characteristics of the groups, there were more patients < 55 years old, more patients in CR (68% versus 32%), and fewer patients with primary refractory disease in the CC group than in the HMA group (10% versus 19%, P < .001). Patients with primary refractory disease had worse outcomes than those in CR with regard to OS (hazard ratio [HR], 2.42; 95% confidence interval [CI], 1.41 to 4.13; P = .001), RFS (HR, 2.27; 95% CI, 1.37 to 3.76; P = .001), and NRM (HR, 2.49; 95% CI, 1.18 to 5.26; P = .016). In addition, an adverse effect of IPSS-R cytogenetic risk group was evident for RFS. In summary, outcomes after HSCT are similar for patients receiving HMA compared with those receiving CC, despite the higher proportion of patients with primary refractory disease in the HMA group.

Details

Original languageEnglish
Pages (from-to)1615-20
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number9
Publication statusPublished - Sep 2016

Keywords

  • Journal Article